

# **Certificate of Analysis**

Print Date: Sep 3<sup>rd</sup> 2021

www.tocris.com

Product Name: Vemurafenib Catalog No.: 7309 Batch No.: 1

CAS Number: 918504-65-1

IUPAC Name: N-[3-[[5-(4-Chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl]-2,4-difluorophenyl]-1-propanesulfonamide

### 1. PHYSICAL AND CHEMICAL PROPERTIES

**Batch Molecular Formula:**  $C_{23}H_{18}CIF_2N_3O_3S$ .

Batch Molecular Weight: 489.92

Physical Appearance: Off White solid
Solubility: DMSO to 100 mM
Storage: Store at -20°C

**Batch Molecular Structure:** 

### 2. ANALYTICAL DATA

**HPLC:** Shows 98.9% purity

<sup>1</sup>H NMR: Consistent with structure

Mass Spectrum: Consistent with structure

Microanalysis: Carbon Hydrogen Nitrogen

Theoretical 56.39 3.7 8.58 Found 56.07 3.76 8.32



### **Product Information**

Print Date: Sep 3<sup>rd</sup> 2021

www.tocris.com

Product Name: Vemurafenib Catalog No.: 7309 Batch No.: 1

CAS Number: 918504-65-1

IUPAC Name: N-[3-[[5-(4-Chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl]-2,4-difluorophenyl]-1-propanesulfonamide

### **Description:**

Vemurafenib is a potent inhibitor of BRAF $^{V600E}$ , C-Raf and wild type B-Raf (IC $_{50}$  values are 13-31 nM, 6.7-48 nM and 100-160 nM, respectively. Vemurafenib also inhibits SRMS, ACK1 KHS1, FGR (IC $_{50}$  values are 18 nM, 19 nM, 51 nM and 63 nM, respectively). Vemurafenib shows antitumor activity and induces autophagy in BRAF-mutant thyroid cancer cells.

#### **Physical and Chemical Properties:**

Batch Molecular Formula: C<sub>23</sub>H<sub>18</sub>CIF<sub>2</sub>N<sub>3</sub>O<sub>3</sub>S.

Batch Molecular Weight: 489.92 Physical Appearance: Off White solid

## **Minimum Purity:** ≥98%

### **Batch Molecular Structure:**

Storage: Store at -20°C

### Solubility & Usage Info:

DMSO to 100 mM

#### Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. Our standard recommendations are:

SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

### References:

Wang et al (2017) Targeting autophagy sensitizes BRAF-mutant thyroid cancer to vemurafenib. J.Clin.Endocrinol.Metab. 102 634. PMID: 27754804.

**Ibrahim** *et al* (2013) Chapter twenty-six - case history: vemurafenib, a potent, selective, and first-in-class inhibitor of mutant BRAF for the treatment of metastatic melanoma. Annu.Rep.Med.Chem. *48* 435.

Davis and Schlessinger (2012) The genesis of zelboraf: targeting mutant B-Raf in melanoma. J.Cell.Biol. 199 15. PMID: 23027900.